ClinicalTrials.gg
CompletedNCT01289119Updated Mar 22, 2013Results posted

Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes

A Phase 3 interventional study of Alogliptin and Placebo to alogliptin in Diabetes Mellitus, Type 2, sponsored by Takeda. Completed at 21 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-03-22.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
506
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing alogliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. alogliptin · Diabetes Mellitus, Type 2.

Enrollment
11th of 39
506 · median 329
Started
2010
the only one that year
Phase 3
16 of 39
none open now
Registered
21st of 39
by date
Lead sponsor
30 of 39
Takeda

Among the 39 studies testing alogliptin in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is the only one that started in 2010, is one of 16 in phase 3, and was the 21st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 39 studies testing alogliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About alogliptin

alogliptin: first FDA approval 2013 (NESINA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing alogliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of the study is to determine the efficacy of alogliptin compared to placebo when given alone or as add-on therapy to metformin or add-on to pioglitazone (with or without metformin).

Read the detailed description

Diabetes is a chronic illness associated with microvascular complications such as nephropathy (kidney disease), retinopathy (eye damage) and neuropathy (nervous system damage). Diabetes is also associated with macrovascular complications including cardiovascular disease (heart disease), stroke and peripheral vascular disease (narrowing or blockage of blood vessels). These complications are associated with reduced quality of life and increased morbidity and mortality.

Takeda is developing SYR-322 (alogliptin) for improvement of glycemic control in patients with Type 2 diabetes mellitus.

Evaluations of alogliptin and its clinical efficacy have been conducted in multiple countries including the United States and Japan. This study will be conducted as a multi-center clinical trial in order to validate the efficacy and safety of alogliptin on type 2 diabetes population within Asia.

Participants who qualified for the study were stratified into 1 of the 3 therapy groups based upon their background antidiabetic therapy before being randomized 1:1 to receive either alogliptin 25 mg once daily or matching placebo once daily.

  • Monotherapy group - patients who had been treated with diet and exercise for at least 2 months prior to screening.
  • Add-on to metformin therapy group - patients who had been treated with metformin for at least 3 months and at a stable dose (≥1000 mg/day) for at least 8 weeks prior to screening.
  • Add-on to pioglitazone therapy group - patients who had been treated with a stable dose of pioglitazone alone or in combination with metformin at a stable dose for at least 8 weeks prior to screening.
03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Type 2 Diabetes Mellitus
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a historical diagnosis of Type 2 Diabetes Mellitus.
  • Has a between acceptable range.
  • Is experiencing inadequate glycemic control.
  • Body weight keeps constant.
  • Females of and males who are sexually active agree to use routinely adequate from signing of throughout the duration of the study and for 30 days after last dose.

Exclusion criteria

Exclusion Criteria:

  • Has participated in another clinical study within the past 90 days or has received any compound within 30 days prior to randomization.
  • Has a systolic blood pressure beyond the acceptable range at Screening visit.
  • Has Class III or IV heart failure regardless of therapy.
  • Has any major illness or debility that in the investigator's opinion prohibits the subject from completing the study.
  • Has a history of or allergies to any DPP-4 inhibitor.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
506 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.

    Drug: Placebo to alogliptin

  • Experimental
    Alogliptin Monotherapy

    Participants received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.

    Drug: Alogliptin

  • Other
    Metformin

    Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.

    Drug: Placebo to alogliptin · Drug: Metformin

  • Experimental
    Metformin + Alogliptin Add-on Therapy

    Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.

    Drug: Alogliptin · Drug: Metformin

  • Other
    Pioglitazone

    Participants continued to receive their stable dose of pioglitazone with or without metformin, and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.

    Drug: Placebo to alogliptin · Drug: Pioglitazone

  • Experimental
    Pioglitazone + Alogliptin Add-on Therapy

    Participants continued to receive their stable dose of pioglitazone with or without metformin and also received alogliptin, 25 mg tablets orally once daily for up to 16 weeks.

    Drug: Alogliptin · Drug: Pioglitazone

Interventions

  • Alogliptin tablets

    Also known as: SYR-322

  • DrugPlacebo to alogliptin

    Alogliptin placebo-matching tablets.

  • Stable metformin dose

    Also known as: Fortamet, Glucophage, Glumetza

  • Stable pioglitazone dose

    Also known as: Actos

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c)

    The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 16. Least squares means are derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect, and baseline HbA1c as a covariate for the monotherapy, baseline HbA1c with baseline metformin dose as covariates for the metformin therapy, baseline HbA1c with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.

    Time frame: Baseline and Week 16.

Secondary outcomes

  1. Change From Baseline in HbA1c Over Time

    The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at Weeks 4, 8 and 12. Least squares means are derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect, and baseline HbA1c as a covariate for the monotherapy, baseline HbA1c with baseline metformin dose as covariates for the metformin therapy, baseline HbA1c with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.

    Time frame: Baseline and Weeks 4, 8 and 12.

  2. Change From Baseline in Fasting Plasma Glucose Over Time

    The change from Baseline in fasting plasma glucose (FPG) at Weeks 4, 8, 12 and 16. Least squares means are derived from an ANCOVA model with treatment as a fixed effect, and baseline FPG as a covariate for the monotherapy, baseline FPG with baseline metformin dose as covariates for the metformin therapy, baseline FPG with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.

    Time frame: Baseline and Weeks 4, 8, 12 and 16.

  3. Percentage of Participants With Marked Hyperglycemia

    Marked Hyperglycemia was defined as fasting plasma glucose greater than or equal to 200 mg/dL (11.1 mmol/L).

    Time frame: Randomization to Week 16.

  4. Change From Baseline in Body Weight

    The change between body weight measured at Baseline and body weight measured at Weeks 8 and 16. The least squares means are derived from an ANCOVA model with treatment as a fixed effect, and baseline body weight as a covariate for the monotherapy, baseline body weight with baseline metformin dose as covariates for the add-on to metformin therapy, baseline body weight with baseline metformin therapy status and baseline pioglitazone dose as covariates for the add-on to pioglitazone therapy.

    Time frame: Baseline and Weeks 8 and 16.

  5. Percentage of Participants With HbA1c ≤6.5% at Week 16

    Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 6.5% at Week 16.

    Time frame: Week 16

  6. Percentage of Participants With HbA1c ≤7.0% at Week 16

    Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 7.0% at Week 16.

    Time frame: Week 16

  7. Percentage of Participants With HbA1c ≤7.5% at Week 16

    Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 7.5% at Week 16.

    Time frame: Week 16

  8. Percentage of Participants With a Decrease in HbA1c ≥ 0.5%

    Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 0.5% at Week 16.

    Time frame: Baseline and Week 16

  9. Percentage of Participants With a Decrease in HbA1c ≥1.0%

    Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.0% at Week 16.

    Time frame: Baseline and Week 16

  10. Percentage of Participants With a Decrease in HbA1c ≥1.5%

    Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.5% at Week 16.

    Time frame: Baseline and Week 16.

  11. Percentage of Participants With a Decrease in HbA1c ≥2.0%

    Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 2.0% at Week 16.

    Time frame: Baseline and Week 16.

07

Results

Posted Mar 22, 2013

Participant flow

Participants took part in the study at 30 investigative sites in China, Taiwan province and Hong Kong from 23 December 2010 to 19 December 2011.

Participant flow — Overall Study
MilestonePlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on Therapy
Started939298996361
Treated929298996361
Completed848389935857
Not completed999654
Withdrew: Adverse event210210
Withdrew: Major protocol deviation213021
Withdrew: Lost to follow-up030001
Withdrew: Withdrawal by subject424311
Withdrew: Pregnancy010000
Withdrew: Lack of efficacy011111
Withdrew: Other101000

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin (HbA1c)

The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 16. Least squares means are derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect, and baseline HbA1c as a covariate for the monotherapy, baseline HbA1c with baseline metformin dose as covariates for the metformin therapy, baseline HbA1c with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.

Time frame:
Baseline and Week 16.
Reported as:
Least squares mean · percentage glycosylated hemoglobin
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
percentage glycosylated hemoglobinPlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on Therapy
Change From Baseline in Glycosylated Hemoglobin (HbA1c)-0.42 ± 0.074-0.99 ± 0.074-0.22 ± 0.065-0.91 ± 0.065-0.25 ± 0.097-0.76 ± 0.101
Statistical analysis
  • Placebo vs Alogliptin Monotherapy · ANCOVA · p = <0.001 · Ls mean difference: -0.58 · 95% CI -0.78 to -0.37ANCOVA model with treatment as a fixed effect, and baseline HbA1c as a covariate.
  • Metformin vs Metformin + Alogliptin Add-on Therapy · ANCOVA · p = <0.001 (ANCOVA model with treatment as a fixed effect, and baseline HbA1c with baseline metformin dose as covariates.) · Ls mean difference: -0.69 · 95% CI -0.87 to -0.51
  • Pioglitazone vs Pioglitazone + Alogliptin Add-on Therapy · ANCOVA · p = <0.001 · Ls mean difference: -0.52 · 95% CI -0.75 to -0.28ANCOVA model with treatment as a fixed effect, and baseline HbA1c with baseline metformin therapy status and baseline pioglitazone dose as covariates.
SecondaryChange From Baseline in HbA1c Over Time

The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at Weeks 4, 8 and 12. Least squares means are derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect, and baseline HbA1c as a covariate for the monotherapy, baseline HbA1c with baseline metformin dose as covariates for the metformin therapy, baseline HbA1c with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.

Time frame:
Baseline and Weeks 4, 8 and 12.
Reported as:
Least squares mean · percentage glycosylated hemoglobin
Change From Baseline in HbA1c Over Time
percentage glycosylated hemoglobinPlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on Therapy
Week 4 (n=90, 88, 97, 98, 63, 60)-0.24 ± 0.059-0.56 ± 0.059-0.15 ± 0.036-0.43 ± 0.036-0.09 ± 0.064-0.44 ± 0.066
Week 8 (n=90, 90, 97, 98, 63, 60)-0.39 ± 0.068-0.86 ± 0.068-0.15 ± 0.057-0.66 ± 0.057-0.31 ± 0.094-0.70 ± 0.098
Week 12 (n=90, 90, 97, 98, 63, 60)-0.41 ± 0.078-0.99 ± 0.078-0.24 ± 0.069-0.86 ± 0.068-0.25 ± 0.102-0.77 ± 0.106
SecondaryChange From Baseline in Fasting Plasma Glucose Over Time

The change from Baseline in fasting plasma glucose (FPG) at Weeks 4, 8, 12 and 16. Least squares means are derived from an ANCOVA model with treatment as a fixed effect, and baseline FPG as a covariate for the monotherapy, baseline FPG with baseline metformin dose as covariates for the metformin therapy, baseline FPG with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.

Time frame:
Baseline and Weeks 4, 8, 12 and 16.
Reported as:
Least squares mean · mmol/L
Change From Baseline in Fasting Plasma Glucose Over Time
mmol/LPlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on Therapy
Week 4 (n=89, 87, 97, 97, 63, 60)-0.331 ± 0.1221-0.719 ± 0.1235-0.251 ± 0.1454-0.985 ± 0.14540.284 ± 0.2505-0.985 ± 0.2603
Week 8 (n=89, 89, 97, 97, 63, 60)-0.330 ± 0.1224-1.015 ± 0.1224-0.235 ± 0.1397-1.265 ± 0.1397-0.038 ± 0.2503-0.924 ± 0.2600
Week 12 (n=89, 89, 97, 97, 63, 60)-0.411 ± 0.1515-1.123 ± 0.1515-0.335 ± 0.1600-1.270 ± 0.1600-0.187 ± 0.2484-1.177 ± 0.2581
Week 16 (n=89, 89, 97, 97, 63, 60)-0.317 ± 0.1556-1.243 ± 0.1556-0.512 ± 0.1565-1.240 ± 0.1565-0.114 ± 0.2579-1.070 ± 0.2679
SecondaryPercentage of Participants With Marked Hyperglycemia

Marked Hyperglycemia was defined as fasting plasma glucose greater than or equal to 200 mg/dL (11.1 mmol/L).

Time frame:
Randomization to Week 16.
Reported as:
Number · percentage of participants
Percentage of Participants With Marked Hyperglycemia
percentage of participantsPlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on Therapy
Percentage of Participants With Marked Hyperglycemia16.94.525.813.423.88.3
SecondaryChange From Baseline in Body Weight

The change between body weight measured at Baseline and body weight measured at Weeks 8 and 16. The least squares means are derived from an ANCOVA model with treatment as a fixed effect, and baseline body weight as a covariate for the monotherapy, baseline body weight with baseline metformin dose as covariates for the add-on to metformin therapy, baseline body weight with baseline metformin therapy status and baseline pioglitazone dose as covariates for the add-on to pioglitazone therapy.

Time frame:
Baseline and Weeks 8 and 16.
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight
kgPlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on Therapy
Week 8 (n=87, 86, 94, 96, 63, 59)-1.04 ± 0.210-0.71 ± 0.211-0.82 ± 0.170-0.43 ± 0.168-0.74 ± 0.286-0.15 ± 0.304
Week 16 (n=88, 87, 94, 96, 63, 59)-1.55 ± 0.244-0.89 ± 0.245-1.06 ± 0.219-0.76 ± 0.217-0.68 ± 0.364-0.10 ± 0.388
SecondaryPercentage of Participants With HbA1c ≤6.5% at Week 16

Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 6.5% at Week 16.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c ≤6.5% at Week 16
percentage of participantsPlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on Therapy
Percentage of Participants With HbA1c ≤6.5% at Week 1612.236.74.121.49.530.0
SecondaryPercentage of Participants With HbA1c ≤7.0% at Week 16

Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 7.0% at Week 16.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c ≤7.0% at Week 16
percentage of participantsPlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on Therapy
Percentage of Participants With HbA1c ≤7.0% at Week 1630.063.325.855.131.761.7
SecondaryPercentage of Participants With HbA1c ≤7.5% at Week 16

Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 7.5% at Week 16.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c ≤7.5% at Week 16
percentage of participantsPlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on Therapy
Percentage of Participants With HbA1c ≤7.5% at Week 1653.381.150.580.647.685.0
SecondaryPercentage of Participants With a Decrease in HbA1c ≥ 0.5%

Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 0.5% at Week 16.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in HbA1c ≥ 0.5%
percentage of participantsPlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on Therapy
Percentage of Participants With a Decrease in HbA1c ≥ 0.5%41.184.437.170.442.976.7
SecondaryPercentage of Participants With a Decrease in HbA1c ≥1.0%

Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.0% at Week 16.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in HbA1c ≥1.0%
percentage of participantsPlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on Therapy
Percentage of Participants With a Decrease in HbA1c ≥1.0%20.050.09.345.919.046.7
SecondaryPercentage of Participants With a Decrease in HbA1c ≥1.5%

Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.5% at Week 16.

Time frame:
Baseline and Week 16.
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in HbA1c ≥1.5%
percentage of participantsPlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on Therapy
Percentage of Participants With a Decrease in HbA1c ≥1.5%7.823.31.022.47.98.3
SecondaryPercentage of Participants With a Decrease in HbA1c ≥2.0%

Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 2.0% at Week 16.

Time frame:
Baseline and Week 16.
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in HbA1c ≥2.0%
percentage of participantsPlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on Therapy
Percentage of Participants With a Decrease in HbA1c ≥2.0%2.28.90.09.21.63.3

Adverse events

Collected over Treatment-emergent adverse events (TEAE) were defined as any adverse events that started on or after the date of the first dose of double-blind study drug and within 14 days after the date of the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/92 (2.2%)11/92 (12%)
Alogliptin Monotherapy—2/92 (2.2%)12/92 (13%)
Metformin—3/98 (3.1%)8/98 (8.2%)
Metformin + Alogliptin Add-on Therapy—0/99 (0%)7/99 (7.1%)
Pioglitazone—0/63 (0%)14/63 (22.2%)
Pioglitazone + Alogliptin Add-on Therapy—1/61 (1.6%)18/61 (29.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on Therapy
Lacunar infarctionNervous system disorders0/920/920/980/990/631/61
Pancreatitis acuteGastrointestinal disorders1/920/920/980/990/630/61
Cholangitis acuteHepatobiliary disorders0/921/920/980/990/630/61
CellulitisInfections and infestations1/920/920/980/990/630/61
Intraductal papilloma of breastNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/921/920/980/990/630/61
Atrial fibrillationCardiac disorders0/920/921/980/990/630/61
Coronary artery diseaseCardiac disorders0/920/921/980/990/630/61
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/920/921/980/990/630/61
HypertensionVascular disorders0/920/921/980/990/630/61
Most frequent other events
Most frequent other events
EventPlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on Therapy
HyperlipidaemiaMetabolism and nutrition disorders1/926/920/980/994/6313/61
Upper respiratory tract infectionInfections and infestations3/925/925/983/996/632/61
Urinary tract infectionInfections and infestations6/922/922/982/991/634/61
Blood triglycerides increasedInvestigations1/922/922/982/994/630/61

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on TherapyTotal
Mean53.1 ± 8.8851.6 ± 10.4153.2 ± 9.4653.0 ± 9.8851.8 ± 10.3752.6 ± 9.4452.6 ± 9.71
Age, Customized
Age, Customized(participants)PlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on TherapyTotal
<65 Years818086855652440
≥65 years121212147966
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on TherapyTotal
Female393750482433231
Male545548513928275
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on TherapyTotal
Number939298996361506
Region of Enrollment
Region of Enrollment(participants)PlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on TherapyTotal
Taiwan1023006
Hong Kong1224009
China919094926361491
Height
Height(cm)PlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on TherapyTotal
Mean165.4 ± 7.19165.9 ± 8.61164.8 ± 8.47165.7 ± 9.06166.2 ± 8.87163.0 ± 7.06165.2 ± 8.31
Weight
Weight(kg)PlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on TherapyTotal
Mean70.86 ± 10.46471.16 ± 11.06569.67 ± 11.79271.20 ± 13.47372.44 ± 11.98967.59 ± 11.98970.55 ± 11.856
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)PlaceboAlogliptin MonotherapyMetforminMetformin + Alogliptin Add-on TherapyPioglitazonePioglitazone + Alogliptin Add-on TherapyTotal
Mean25.86 ± 3.00225.79 ± 3.08625.54 ± 2.87625.75 ± 3.12226.13 ± 3.03125.32 ± 3.22325.73 ± 3.042

4 further baseline measures are reported on the registry.

08

Study locations

21 sites
  • Beijing, Beijing, China
  • Fuzhou, Fujian, China
  • Xiamen, Fujian, China
  • Guangzhou, Guangdong, China
  • Haikou, Hainan, China
  • Ha'erbin, Heilongjiang, China
  • Jingzhou, Hubei, China
  • Shiyan, Hubei, China
  • Changsha, Hunan, China
  • Wuxi, Jiangsu, China
  • Nanchang, Jiangxi, China
  • Changchun, Jilin, China
  • Shenyang, Liaoning, China
  • Jinan, Shandong, China
  • Shanghai, Shanghai, China
  • Xi'an, Shanxi, China
  • Tianjin, Tianjin, China
  • Kunming, Yunnan, China
  • Hangzhou, Zhejiang, China
  • Hong Kong, Hong Kong
  • Taipei County, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2011
First posted
Feb 3, 2011
Start
Dec 2010
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results first posted
Mar 22, 2013
Last update
Mar 22, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01289119
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 3, 2011
Start date
Dec 2010
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
Mar 22, 2013
Last update
Mar 22, 2013

Study contacts

Professor Study Chair
study chair · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alogliptin · Metformin · Pioglitazone

Start the discussion